William Sandborn

Last updated on 2013-08-23T10:01+0300.

About this image

sign

Quotes... Extracted quotes from

William Sandborn said : “These results support the use of the DDS for the company’s lead ulcerative colitis combination product candidate, and potentially for uses of the DDS with other therapeutics to create combination products targeting other GI diseases. By delivering solubilized therapeutics directly to the site of disease in the GI tract, the DDS can potentially improve efficacy through increased localized drug concentration while minimizing harmful side effects associated with systemic drug delivery,” External link

4-traders Wednesday, May 12, 2021 3:24:00 PM EAT

William Sandborn said : “Ulcerative colitis is poorly managed with current therapeutics, in part due to the inability to get sufficient drug concentrations at the site of disease without side effects. We believe the DDS platform and PGN-001 and PGN-600 have the potential to significantly improve patient outcomes by producing high drug concentrations locally at the site of disease to improve efficacy while limiting systemic exposure to ensure safety,” External link

news-yahoo Friday, November 6, 2020 4:09:00 PM EAT

William Sandborn said ( about True North ) : “The data from the Zeposia True North trial demonstrate patients with moderate to severe ulcerative colitis achieved clinically meaningful improvements in key clinical, endoscopic and mucosal healing endpoints,” External link

4-traders Sunday, October 11, 2020 7:20:00 AM EAT

William Sandborn said : “These data indicate that the investigational subcutaneous formulation of vedolizumab seems to have a similar safety profile to the intravenous formulation,” External link

4-traders Friday, February 14, 2020 6:06:00 PM EAT

William Sandborn said : "These data indicate that the investigational subcutaneous formulation of vedolizumab seems to have a similar safety profile to the intravenous formulation," External link

afp-en Friday, February 14, 2020 5:37:00 PM EAT

William Sandborn said : “Direct administration of drug therapies via ingestible technologies shows tremendous promise to improve treatment outcomes in patients with gastrointestinal diseases,” External link

4-traders Monday, October 28, 2019 11:35:00 PM EAT

William Sandborn said : "The symptoms of Crohn's disease can cause significant distress to many patients, which is why it's important to find a treatment that can act rapidly to reduce the impact of the disease. These new results from the UNITI-1 trial are encouraging because they demonstrate that treatment with ustekinumab may begin to reduce patient reported symptoms of Crohn's disease within just 1-2 weeks for a number of patients," External link

finanznachrichten-en Monday, October 30, 2017 6:37:00 PM EAT

William Sandborn said : "In a small Phase 1b trial not statistically powered to demonstrate efficacy, it is remarkable to see compelling directional change in local biological effect for patients receiving TD-1473, particularly a change in rectal bleeding and endoscopic subscores. Further, these effects were measured after just four weeks of treatment, a timeframe shorter than the typical induction endpoint in ulcerative colitis trials," External link

prnewswire Tuesday, August 8, 2017 11:59:00 PM EAT

William Sandborn said : "Maintaining control of disease symptoms is paramount in the treatment of Crohn's disease. The two-year clinical response and remission rates from the IM-UNITI study provide further evidence that ustekinumab can be an effective therapeutic option for people living with this chronic and often debilitating disease," External link

finanznachrichten-en Friday, February 17, 2017 12:19:00 PM EAT

William Sandborn said : "Maintaining control of disease symptoms is paramount in the treatment of Crohn's disease. The two-year clinical response and remission rates from the IM-UNITI study provide further evidence that ustekinumab can be an effective therapeutic option for people living with this chronic and often debilitating disease," External link

afp-en Friday, February 17, 2017 11:50:00 AM EAT

William Sandborn said : “At this early 12-week timepoint, we’re looking at the proportion of patients who had a 25 percent or greater endoscopic improvement, suggesting mucosal healing is underway in these patients,” External link

4-traders Monday, September 12, 2016 2:46:00 PM EAT

William Sandborn said : "The totality of the induction and maintenance data over the course of one year show the potential of this biologic therapy in inducing and maintaining a clinically relevant therapeutic effect in patients with moderate to severe Crohn's disease," External link

prnewswire Tuesday, May 24, 2016 3:43:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
professor57.14%EN02/17/201717/02/2017
directeur28.57%FR08/22/201322/08/2013
diretor14.29%PT08/22/201322/08/2013
Names Lang Count
William SandbornEN75.00%
William SandbornFR12.50%
William SandbornPT12.50%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Tuesday, October 4, 2022

3:58:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

William Sandborn

Last updated on 2013-08-23T10:01+0300.

About this image

sign

Quotes... Extracted quotes from

William Sandborn said : “These results support the use of the DDS for the company’s lead ulcerative colitis combination product candidate, and potentially for uses of the DDS with other therapeutics to create combination products targeting other GI diseases. By delivering solubilized therapeutics directly to the site of disease in the GI tract, the DDS can potentially improve efficacy through increased localized drug concentration while minimizing harmful side effects associated with systemic drug delivery,” External link

4-traders Wednesday, May 12, 2021 3:24:00 PM EAT

William Sandborn said : “Ulcerative colitis is poorly managed with current therapeutics, in part due to the inability to get sufficient drug concentrations at the site of disease without side effects. We believe the DDS platform and PGN-001 and PGN-600 have the potential to significantly improve patient outcomes by producing high drug concentrations locally at the site of disease to improve efficacy while limiting systemic exposure to ensure safety,” External link

news-yahoo Friday, November 6, 2020 4:09:00 PM EAT

William Sandborn said ( about True North ) : “The data from the Zeposia True North trial demonstrate patients with moderate to severe ulcerative colitis achieved clinically meaningful improvements in key clinical, endoscopic and mucosal healing endpoints,” External link

4-traders Sunday, October 11, 2020 7:20:00 AM EAT

William Sandborn said : “These data indicate that the investigational subcutaneous formulation of vedolizumab seems to have a similar safety profile to the intravenous formulation,” External link

4-traders Friday, February 14, 2020 6:06:00 PM EAT

William Sandborn said : "These data indicate that the investigational subcutaneous formulation of vedolizumab seems to have a similar safety profile to the intravenous formulation," External link

afp-en Friday, February 14, 2020 5:37:00 PM EAT

William Sandborn said : “Direct administration of drug therapies via ingestible technologies shows tremendous promise to improve treatment outcomes in patients with gastrointestinal diseases,” External link

4-traders Monday, October 28, 2019 11:35:00 PM EAT

William Sandborn said : "The symptoms of Crohn's disease can cause significant distress to many patients, which is why it's important to find a treatment that can act rapidly to reduce the impact of the disease. These new results from the UNITI-1 trial are encouraging because they demonstrate that treatment with ustekinumab may begin to reduce patient reported symptoms of Crohn's disease within just 1-2 weeks for a number of patients," External link

finanznachrichten-en Monday, October 30, 2017 6:37:00 PM EAT

William Sandborn said : "In a small Phase 1b trial not statistically powered to demonstrate efficacy, it is remarkable to see compelling directional change in local biological effect for patients receiving TD-1473, particularly a change in rectal bleeding and endoscopic subscores. Further, these effects were measured after just four weeks of treatment, a timeframe shorter than the typical induction endpoint in ulcerative colitis trials," External link

prnewswire Tuesday, August 8, 2017 11:59:00 PM EAT

William Sandborn said : "Maintaining control of disease symptoms is paramount in the treatment of Crohn's disease. The two-year clinical response and remission rates from the IM-UNITI study provide further evidence that ustekinumab can be an effective therapeutic option for people living with this chronic and often debilitating disease," External link

finanznachrichten-en Friday, February 17, 2017 12:19:00 PM EAT

William Sandborn said : "Maintaining control of disease symptoms is paramount in the treatment of Crohn's disease. The two-year clinical response and remission rates from the IM-UNITI study provide further evidence that ustekinumab can be an effective therapeutic option for people living with this chronic and often debilitating disease," External link

afp-en Friday, February 17, 2017 11:50:00 AM EAT

William Sandborn said : “At this early 12-week timepoint, we’re looking at the proportion of patients who had a 25 percent or greater endoscopic improvement, suggesting mucosal healing is underway in these patients,” External link

4-traders Monday, September 12, 2016 2:46:00 PM EAT

William Sandborn said : "The totality of the induction and maintenance data over the course of one year show the potential of this biologic therapy in inducing and maintaining a clinically relevant therapeutic effect in patients with moderate to severe Crohn's disease," External link

prnewswire Tuesday, May 24, 2016 3:43:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
professor57.14%EN02/17/201717/02/2017
directeur28.57%FR08/22/201322/08/2013
diretor14.29%PT08/22/201322/08/2013
Names Lang Count
William SandbornEN75.00%
William SandbornFR12.50%
William SandbornPT12.50%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Tuesday, October 4, 2022

3:58:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer